Role of Booster Dose on Antibody Titer after Recombinant Hepatitis B Vaccination

Authors

  • Md Abdul Ahad Assistant Professor, Department of Gastroenterology, Rajshahi Medical College
  • Md Abdul Alim Assistant Professor, Department of Gastroenterology, Rajshahi Medical College
  • Abhijit Guho Medical Officer, Department of Microbiology, Rajshahi Medical College
  • Quazi Tarikul Islam Professor and Head, Department of Medicine, Rajshahi Medical College
  • Khan Abul Kalam Azad Professor, Department of Medicine. Dhaka Medical College, Dhaka

DOI:

https://doi.org/10.3329/jom.v10i2.2817

Keywords:

Hepatitis B vaccine

Abstract

Hepatitis B virus infection is an important public health problem with significant morbidity and mortality. Recombinant hepatitis B vaccination for the prevention of hepatitis B virus infection is in practice in different parts of the world since its availability in 1986. Government of Bangladesh has also included hepatitis B vaccine in EPI schedule since 2005. This study was carried out to assess the seroconversion status among hepatitis B vaccinated individuals. A total of 190 individuals including 150 vaccinated persons and 40 non-vaccinated apparently healthy individuals were included as study population. Sources of vaccinated persons were from both EPI and non-EPI schedule of vaccination. Age and sex matched non-vaccinated individuals served as controls for the study. All individuals constituting the study population were screened for HBsAg by Immunochromatographic strip test and only HBsAg-negative persons were included for estimation of their anti-HBs titer. Out of 150 vaccinated individuals, 133(88.67%) were found to have anti-HBs titer in the protective level (e"10 IU/L), while 17(11.33%) individuals had anti-HBs titer below the protective level (<10 IU/L). All non-vaccinated controls had anti- HBs titers below the protective level. Immune response developed among vaccinated individuals, 67.78%, 23.33% and 8.89% were good-responders, hypo-responders and non-responders respectively. Mean titer of anti-HBs was found significantly higher among recipients who received booster dose than those who received 3 doses schedule (863.39 IU/L vs. 262.40 IU/L), indicating high antibody titer develops after booster dose. Vaccinated group included 85 (56.67%) men and 65 (43.33%) women with protective level of anti-HBs titer found in 85.88% male and 92.31% female individuals.  

doi: 10.3329/jom.v10i2.2817

J MEDICINE 2009; 10 : 67-76

Downloads

Download data is not yet available.
Abstract
112
PDF
295

Author Biography

Md Abdul Ahad, Assistant Professor, Department of Gastroenterology, Rajshahi Medical College

Assistant Professor, Department of Gastroenterology, Rajshahi Medical
College, Bangladesh

Downloads

How to Cite

Ahad, M. A., Alim, M. A., Guho, A., Islam, Q. T., & Azad, K. A. K. (2009). Role of Booster Dose on Antibody Titer after Recombinant Hepatitis B Vaccination. Journal of Medicine, 10(2), 67–76. https://doi.org/10.3329/jom.v10i2.2817

Issue

Vol. 10 No. 2 (2009)

Section

Original Articles

License

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

  1. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).